BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27910856)

  • 21. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.
    Kaoutari AE; Fraunhoffer NA; Hoare O; Teyssedou C; Soubeyran P; Gayet O; Roques J; Lomberk G; Urrutia R; Dusetti N; Iovanna J
    EBioMedicine; 2021 Apr; 66():103332. PubMed ID: 33862584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
    Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
    Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATM- and ATR-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma.
    Chao YY; Huang BM; Peng IC; Lee PR; Lai YS; Chiu WT; Lin YS; Lin SC; Chang JH; Chen PS; Tsai SJ; Wang CY
    J Cell Physiol; 2022 Dec; 237(12):4487-4503. PubMed ID: 36251015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
    Mofid MR; Gheysarzadeh A; Bakhtiyari S
    Pancreatology; 2020 Oct; 20(7):1442-1450. PubMed ID: 32830034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
    Xu W; Wang S; Chen Q; Zhang Y; Ni P; Wu X; Zhang J; Qiang F; Li A; Røe OD; Xu S; Wang M; Zhang R; Zhou J
    Cell Death Dis; 2014 Feb; 5(2):e1055. PubMed ID: 24525731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
    J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule.
    Marchetti C; Zyner KG; Ohnmacht SA; Robson M; Haider SM; Morton JP; Marsico G; Vo T; Laughlin-Toth S; Ahmed AA; Di Vita G; Pazitna I; Gunaratnam M; Besser RJ; Andrade ACG; Diocou S; Pike JA; Tannahill D; Pedley RB; Evans TRJ; Wilson WD; Balasubramanian S; Neidle S
    J Med Chem; 2018 Mar; 61(6):2500-2517. PubMed ID: 29356532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
    Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
    Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells.
    Wu ZZ; Lu HP; Chao CC
    Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
    Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
    Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.
    Gaponova AV; Deneka AY; Beck TN; Liu H; Andrianov G; Nikonova AS; Nicolas E; Einarson MB; Golemis EA; Serebriiskii IG
    Oncotarget; 2017 Mar; 8(12):19156-19171. PubMed ID: 27863405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
    PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
    Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J
    Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.